BRIEF-Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer

3

Oct 8 (Reuters) – Vir Biotechnology, Inc.: * VIR BIOTECHNOLOGY ANNOUNCES PSMA-TARGETED PRO-XTEN® DUAL-MASKED T-CELL ENGAGER VIR-5500 RECEIVED FDA FAST TRACK DESIGNATION FOR THE TREATMENT OF PROSTATE

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)